Reimagining Biotech with Jake Becraft of Strand Therapeutics — Tim’s Founder Kitchen
Jake Becraft, CEO of Strand Therapeutics, discusses the company's RNA genetic medicine technology for cancer, highlighting a patient's remarkable recovery from stage 4 melanoma via the abscopal effect. He critically analyzes the US biotech regulatory landscape, advocating for streamlined clinical trials, and contrasts it with faster international approaches. Becraft also shares lessons on effective advocacy and "platform therapeutics" as a long-term strategy, drawing parallels to companies like SpaceX and Amazon.
- The traditional US biotech capital market is built for "asset sales," where over 90% of companies take an idea from concept to early evidence, then sell it off. Jake Becraft of Strand Therapeutics compares this to real estate development. Read →
- Jake Becraft reveals why genetic medicine's 'delivery' problem isn't one issue, but three: potency, specificity, and the transport mechanism. Apply his framework. Read →
- There's a chasm between a 'good drug' (it works) and a 'good product' (it's scalable, accessible, and affordable for many). Don't confuse the two. Read →
- Jake Becraft reveals why a drug that works for one patient can still be a terrible product for millions. Learn his rule for scalable biotech impact. Read →
- Jake Becraft, CEO of Strand Therapeutics, argues that influencing policymakers and investors in deep tech like biotech isn't about data dumps; it's about emotional connection. His rule: "No one will learn until they care." Read →
- Strand Therapeutics, led by CEO Jake Becraft, developed an RNA genetic medicine that instructs cancer cells to send immune-activating signals. Read →
- Strand Therapeutics uses RNA to reprogram diseased cells, turning them into active participants in their own destruction rather than passive targets. Read →
- Jake Becraft warns US biotech is losing to China on early clinical trials. Our IND system costs millions and takes 18+ months. See the faster CTN model. Read →